FluBlok, a recombinant hemagglutinin influenza vaccine
- PMID: 19453397
- PMCID: PMC4634115
- DOI: 10.1111/j.1750-2659.2008.00053.x
FluBlok, a recombinant hemagglutinin influenza vaccine
Abstract
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
Similar articles
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
-
FluBlok, a next generation influenza vaccine manufactured in insect cells.Biologicals. 2009 Jun;37(3):182-9. doi: 10.1016/j.biologicals.2009.02.014. Epub 2009 Mar 17. Biologicals. 2009. PMID: 19297194 Review.
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28. Vaccine. 2011. PMID: 21277410 Clinical Trial.
-
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9. Vaccine. 2011. PMID: 21835220 Clinical Trial.
-
Production of a novel influenza vaccine using insect cells: protection against drifted strains.Influenza Other Respir Viruses. 2007 Jan;1(1):35-40. doi: 10.1111/j.1750-2659.2006.00007.x. Influenza Other Respir Viruses. 2007. PMID: 19453478 Free PMC article. Review.
Cited by
-
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.Vaccine. 2012 Dec 17;31(1):58-83. doi: 10.1016/j.vaccine.2012.10.083. Epub 2012 Nov 6. Vaccine. 2012. PMID: 23142589 Free PMC article. Review.
-
Development of a Universal Influenza Vaccine.J Immunol. 2019 Jan 15;202(2):392-398. doi: 10.4049/jimmunol.1801054. J Immunol. 2019. PMID: 30617121 Free PMC article. Review.
-
Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.Vaccines (Basel). 2019 Nov 1;7(4):169. doi: 10.3390/vaccines7040169. Vaccines (Basel). 2019. PMID: 31683888 Free PMC article. Review.
-
Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.Ther Adv Vaccines. 2015 Jul;3(4):97-108. doi: 10.1177/2051013615595595. Ther Adv Vaccines. 2015. PMID: 26478817 Free PMC article. Review.
-
Current situation and future direction of Newcastle disease vaccines.Vet Res. 2022 Nov 26;53(1):99. doi: 10.1186/s13567-022-01118-w. Vet Res. 2022. PMID: 36435802 Free PMC article. Review.
References
-
- Wood JM. Standardization of Inactivated Influenza Vaccine; in Nicholson KG, Webster RG Hay AJ (eds): Textbook of Influenza London: Blackwell Science, Ltd, 1998; 333–345.
-
- Centers for Disease Control (CDC) . ACIP. Prevention and control of influenza, recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report (MMWR) 2002; 51:1–31. - PubMed
-
- Huber VC, JA Cullers. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 2008; 10:75–85. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical